Northeast Pharmaceutical Group (000597) Fundamentals 2026 — P/E 26.7x, Revenue Analysis | SniperIQ
Northeast Pharmaceutical Group (000597) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥6.6B, trading at ¥4.66 on the SHZ. This SniperIQ fundamentals page covers Northeast Pharmaceutical Group's valuation (P/E 26.7x, P/B 1.2x), profitability (net margin 3.5%), revenue (¥7.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Northeast Pharmaceutical Group's market cap?
Northeast Pharmaceutical Group (000597) has a market capitalization of approximately ¥6.6B, trading at ¥4.66 on the SHZ. Market cap moves with the live share price.
What is Northeast Pharmaceutical Group's P/E ratio?
Northeast Pharmaceutical Group's trailing twelve-month P/E ratio is 26.7x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Northeast Pharmaceutical Group?
Northeast Pharmaceutical Group runs a net profit margin of 3.5%, a gross margin of 33.7%, and an operating margin of 3.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Northeast Pharmaceutical Group generate?
Northeast Pharmaceutical Group reported revenue of ¥7.0B for fiscal year 2025, with net income of ¥260M and earnings per share (EPS) of 0.18. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Northeast Pharmaceutical Group pay a dividend?
Northeast Pharmaceutical Group offers a trailing dividend yield of about 1.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Northeast Pharmaceutical Group financially healthy?
Northeast Pharmaceutical Group carries a debt-to-equity ratio of 0.33x and a current ratio of 1.15x, with a market beta of 0.07. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Northeast Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Northeast Pharmaceutical Group (000597) the key facts are: market cap ¥6.6B, P/E 26.7x, revenue ¥7.0B, 52-week range 4.09-6.68. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Northeast Pharmaceutical Group's full fundamentals live
Get Northeast Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.